Kisplyx

Lenvatinib, the active ingredient in Kisplyx, is a tyrosine kinase inhibitor presented as an oral formulation for systemic use. It targets several cancers by inhibiting tumor angiogenesis and cell proliferation, and is prescribed for patients with differentiated thyroid carcinoma, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma. The drug works by blocking multiple receptor tyrosine kinases involved in tumor growth, making it a valuable option in advanced disease settings. It is administered under oncologist supervision and requires regular monitoring through blood tests.

GNH USA supplies Kisplyx as a licensed, GDP-compliant international pharmaceutical supplier serving oncology centres worldwide.

Lenvatinib is indicated for solid tumours where inhibition of angiogenic signalling pathways is required.

Differentiated thyroid carcinoma: improves progression‑free survival in patients with refractory disease. Renal cell carcinoma: reduces tumour growth and extends survival in advanced cases. Hepatocellular carcinoma: provides therapeutic benefit and prolongs overall survival. Endometrial carcinoma: offers an effective treatment option for advanced or recurrent disease.

Lenvatinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypertension: elevated blood pressure requiring monitoring and possible antihypertensive therapy. - Diarrhea: may be mild to moderate and managed with supportive care. - Fatigue: persistent tiredness that can affect daily activities. - Decreased appetite: reduced food intake leading to weight loss.

Serious or Rare Side Effects: - Hepatic failure: severe liver injury requiring immediate medical attention. - Severe bleeding: gastrointestinal or intracranial hemorrhage. - Perforation of gastrointestinal tract: risk of ulceration and perforation. - Cardiac dysfunction: heart failure or reduced ejection fraction.

Patients receiving Lenvatinib should be closely monitored for safety concerns.

Monitor blood pressure: check regularly and treat hypertension promptly. Assess liver function: perform baseline and periodic liver enzyme tests. Evaluate for proteinuria: urine analysis to detect kidney involvement. Review concomitant anticoagulants: adjust dosing or avoid if bleeding risk is high. Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lenvatinib can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase Lenvatinib exposure and toxicity. - Anticoagulants (e.g., warfarin): heightened risk of severe bleeding.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers: may reduce drug levels and effectiveness. - Diuretics: can exacerbate electrolyte disturbances. - Antihypertensives: may require dose adjustments to control blood pressure.